Delivering high-quality multiple sclerosis care in Germany: challenges and regional models在德国提供高质量多发性硬化症护理:挑战和区域模式Neurological Research and PracticeIF3.22026-09-070OAAI
Clinical practicability of the cognitive screening battery BICAMS in patients with multiple sclerosis: results of the feasibility study in GermanyNERVENARZTIF1.12021-02-171OAAI
Characterizing cognitive deficits and potential predictors in multiple sclerosis: A large nationwide study applying Brief International Cognitive Assessment for Multiple Sclerosis in standard clinical careneuropsychologyIF1.82020-02-1318PREAI
On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairmentMULTIPLE SCLEROSIS JOURNALIF52019-11-1922PREAI
Real-world persistence and benefit-risk profile of fingolimod over 36 months in GermanyNEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATIONIF7.52019-05-0129OAAI
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEANEUROTHERAPEUTICSIF6.92018-01-0111OAAI
36 MONTHS PANGAEA: A 5-YEAR NON-INTERVENTIONAL STUDY OF SAFETY, EFFICACY AND PHARMACOECONOMIC DATA FOR FINGOLIMOD PATIENTS IN DAILY CLINICAL PRACTICEVALUE IN HEALTHIF62015-11-019OAAI
Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular eventsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.51999-07-012OAAI
Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomyANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.51998-08-0155OAAI